Semax
Synthetic ACTH(4-10) analog studied in neurotrophic research.
Evidence Level
Emerging
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Synthetic ACTH(4-10) analog studied in neurotrophic research.
/ 02
Mechanism of Action
Studied for BDNF/NGF modulation and dopaminergic effects.
/ 03
Research Applications
Cognitive performance and neuroprotection models.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
Semax is a synthetic analog related to the ACTH(4–10) fragment. Research describes effects on BDNF/trkB signaling, neurotrophin expression, synaptic plasticity markers, and neuroprotective endpoints in animal and limited regional human studies.
/ 08
Pathway Role
Sits within neurotrophin and synaptic plasticity signaling pathways in the central nervous system.
/ 09
Biological Targets
/ 10
Research Applications
- Stroke and neurorecovery (regional clinical literature)
- Cognitive function preclinical studies
- Neuroprotection animal models
/ 11
Evidence Summary
Mostly animal and regional literature with some limited human studies in specific clinical contexts.
Evidence Level Rationale
Rated emerging due to limited globally-recognized controlled human trials.
/ 12
Research Observation Timeline
Early Signal Window
Gene expression and behavioral changes in animal studies within hours to days
Primary Study Window
Days to weeks in preclinical and regional clinical studies
Endpoint Type
Gene expression, behavioral, and clinical scale endpoints
Evidence Strength
Emerging
/ 13
Safety & Unknowns
Broader human safety profile is not extensively characterized in international literature.
/ 14
Research Limitations
Reliable general cognitive outcome timeline is not established. Regional study quality varies.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Emerging
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
Selank
Synthetic tuftsin analog studied in anxiolytic-like research.
Dihexa
Angiotensin IV analog studied in synaptogenesis research.
Cerebrolysin
Neuropeptide preparation studied in neuroregeneration research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.